NCT04224857View on ClinicalTrials.gov

SAD/MAD Study in Healthy Subjects and Adults With UC to Evaluate Safety, Tolerability, PK, PD of AMT-101

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

April 1, 2019

Primary Completion Date

April 30, 2020

Study Completion Date

April 30, 2020

Conditions
Ulcerative Colitis
Interventions
DRUG

AMT-101

Single or daily dosing at doses A, B, C, D, E, F

DRUG

Placebos

Single or daily dosing at doses A, B, C, D, E, F

Trial Locations (4)

Unknown

LLC ARENSIA Exploratory Medicine, Tbilisi

Charité Research Organisation GmbH, Berlin

ICS ARENSIA Exploratory Medicine SRL, Chisinau

Medical Center of Harmoniya krasy, Department of clinical trials, Kyiv

Sponsors
All Listed Sponsors
lead

Applied Molecular Transport

INDUSTRY

NCT04224857 - SAD/MAD Study in Healthy Subjects and Adults With UC to Evaluate Safety, Tolerability, PK, PD of AMT-101 | Biotech Hunter | Biotech Hunter